|
| Human GHR/Growth Hormone R Protein (LTP10560) |
|
| LTP10560 |
|
| 100ug |
|
|
$406 In stock |
| Pegvisomant, a growth hormone receptor (GHR) antagonist, is a well-known drug that was designed to treat acromegaly. However, recent studies have indicated that the GHR is a "moonlighting" protein that may exhibit dual functions based on its localization in the plasma membrane and nucleus. |
| Recombinant Human GHR/Growth Hormone R Protein is expressed from Expi293 with His tag at the C-terminal. It contains Ala27-Tyr264. |
|
| GHR/Growth Hormone R |
|
| Human |
|
| P10912-1 |
|
| Ala27-Tyr264 |
|
| The protein has a predicted MW of 28.8 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-His |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
